| AMERISOURCEBERGEN |
AMERISOURCEBERGEN |
92%
|
We engage Integrated Commercialization Solutions, a division of AmerisourceBergen Specialty Group, a subsidiary of AmerisourceBergen, to act as our exclusive distributor for commercial shipment and d… |
| CARDINAL-HEALTH-105-INC |
CARDINAL-HEALTH-105-INC |
92%
|
We also contract with numerous wholesale distributors, including Cardinal Health 105, Inc., also known as Specialty Pharmaceutical Services ("Cardinal"), McKesson Corporation and Cencora Inc. (former… |
| INTEGRATED-COMMERCIALIZATION-SOLUTIONS |
INTEGRATED-COMMERCIALIZATION-SOLUTIONS |
92%
|
We engage Integrated Commercialization Solutions, a division of AmerisourceBergen Specialty Group, a subsidiary of AmerisourceBergen, to act as our exclusive distributor for commercial shipment and d… |
| HYPERCON-TECHNOLOGY-COLLABORATION-PARTNERS |
HYPERCON-TECHNOLOGY-COLLABORATION-PARTNERS |
90%
|
The collaboration partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement |
| ORKA |
Oruka Therapeutics, Inc. |
85%
|
les of five commercial products from the Roche collaboration, two commercial products from the Janssen collaboration and one commercial product from each of the Takeda, argenx and BMS collaborations.… |
| ORKA |
Oruka Therapeutics, Inc. |
85%
|
Reciprocal relationship from ORKA graph: Reciprocal relationship from HALO graph: Reciprocal relationship from ORKA graph: Reciprocal relationship from HALO graph: les of five commercial products fro… |
| VRTX |
Vertex Pharmaceuticals Incorporated |
85%
|
les of five commercial products from the Roche collaboration, two commercial products from the Janssen collaboration and one commercial product from each of the Takeda, argenx and BMS collaborations.… |
| VRTX |
Vertex Pharmaceuticals Incorporated |
85%
|
Reciprocal relationship from VRTX graph: Reciprocal relationship from HALO graph: les of five commercial products from the Roche collaboration, two commercial products from the Janssen collaboration … |
| AMPH |
Amphastar Pharmaceuticals, Inc. |
72%
|
nce Marketplaces, has substantial power to implement policy changes or demonstration projects that can quickly and significantly affect how drugs, including our partners’ products, are covered and re… |
| AMPH |
Amphastar Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from AMPH graph: Reciprocal relationship from HALO graph: nce Marketplaces, has substantial power to implement policy changes or demonstration projects that can quickly and si… |
| MCK |
McKesson Corporation |
72%
|
Reciprocal relationship from MCK graph: Reciprocal relationship from HALO graph: Contents Sales, Marketing and Distribution We have two teams of sales specialists, one that provide hospital and surge… |
| MCK |
McKesson Corporation |
72%
|
Contents Sales, Marketing and Distribution We have two teams of sales specialists, one that provide hospital and surgery center customers with the information needed to obtain formulary approval for,… |
| ZLAB |
Zai Lab Limited |
72%
|
Reciprocal relationship from ZLAB graph: Reciprocal relationship from HALO graph: ds. We target large, attractive markets, where ENHANZE-enabled SC delivery has the potential to deliver competitive d… |
| ZLAB |
Zai Lab Limited |
72%
|
ds. We target large, attractive markets, where ENHANZE-enabled SC delivery has the potential to deliver competitive differentiation and other important benefits to our partners, such as larger inject… |
| AMERISOURCEBERGEN-CORPORATION |
AMERISOURCEBERGEN-CORPORATION |
62%
|
XYOSTED. Sales, Marketing and Distribution We have two teams of sales specialists, one that provide hospital and surgery center customers with the information needed to obtain formulary approval for,… |
| AMERISOURCEBERGEN-SPECIALTY-GROUP |
AMERISOURCEBERGEN-SPECIALTY-GROUP |
62%
|
XYOSTED. Sales, Marketing and Distribution We have two teams of sales specialists, one that provide hospital and surgery center customers with the information needed to obtain formulary approval for,… |
| CATALENT-INDIANA-LLC |
CATALENT-INDIANA-LLC |
62%
|
d supply agreement with Teva for an epinephrine auto- injector product to be marketed in the U.S. and Canada. We are the exclusive supplier of the device, which we developed, for Teva’s generic Epine… |
| COMDEL-INNOVATION-INC |
COMDEL-INNOVATION-INC |
62%
|
-injector product with Teva. • ComDel Innovation, Inc., a domestic provider of integrated solutions for product development, tooling, and manufacturing, produces commercial quantities of components f… |
| KNIPPER-HEALTH-INC |
KNIPPER-HEALTH-INC |
62%
|
XYOSTED. Sales, Marketing and Distribution We have two teams of sales specialists, one that provide hospital and surgery center customers with the information needed to obtain formulary approval for,… |
| LONZA-SALES-AG |
LONZA-SALES-AG |
62%
|
d supply agreement with Teva for an epinephrine auto- injector product to be marketed in the U.S. and Canada. We are the exclusive supplier of the device, which we developed, for Teva’s generic Epine… |
| NOLATO-CONTOUR-INC |
NOLATO-CONTOUR-INC |
62%
|
onal contract packaging company, assembles and packages XYOSTED auto-injector products and the OTREXUP auto-injector product for Otter. • Nolato Contour, Inc. produces commercial quantities of compon… |
| PHILLIPS-MEDISIZE-CORPORATION |
PHILLIPS-MEDISIZE-CORPORATION |
62%
|
facturing Services, LLC (“Patheon”) under which Patheon will provide the final fill and finishing steps in the production process of Hylenex recombinant. Devices We also use third parties to manufact… |
| ROCHE-GROUP |
ROCHE-GROUP |
62%
|
nds. We target large, attractive markets, where ENHANZE-enabled SC delivery has the potential to deliver competitive differentiation and other important benefits to our partners, such as larger injec… |
